文献速递淋巴瘤

套细胞淋巴瘤亚型起源、发病机制和临床行为的基因组与表观基因组见解

Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes.
PubMed 文献 · Blood · 2020-01-01

该研究对套细胞淋巴瘤(MCL)两个分子亚型——经典型MCL(cMCL)和白血病型非淋巴结MCL(nnMCL)进行全基因组(n=61)和外显子组(n=21)测序,结合转录组和DNA甲基化谱分析。研究发现开放活跃染色质可能促进t(11;14)(q13;32)易位,鉴定出多个新的MCL驱动基因,复杂结构变异是早期致癌机制,cMCL的结构变异、拷贝数改变和驱动改变数量显著高于nnMCL,基因组复杂性增加与不同临床演变相关。

要点

  • cMCL的结构变异、拷贝数改变和驱动改变数量显著高于nnMCL,ATM改变为cMCL独有。
  • TP53和MYC异常独立于基因组复杂性提供预后价值。
  • 基因组复杂性增加、断裂-融合-桥循环和高DNA甲基化改变定义不同临床演变患者。

核心结论

  • 开放活跃染色质可能促进t(11;14)(q13;32)易位,该易位主要在前体B细胞中由重组激活基因介导获得,8%病例在成熟B细胞中由活化诱导胞苷脱氨酶介导。
  • cMCL的结构变异、拷贝数改变和驱动改变数量显著高于nnMCL,ATM改变为cMCL独有,TP53和TERT改变在nnMCL中略微富集。
  • 基因组复杂性增加、断裂-融合-桥循环和高DNA甲基化改变定义不同临床演变患者,仅TP53和MYC异常独立于基因组复杂性提供预后价值。

研究设计与样本

  • 研究采用全基因组测序(n=61)和外显子组测序(n=21),样本中74%为cMCL、26%为nnMCL,结合转录组和DNA甲基化谱分析,并参考5个MCL表观基因组。

主要发现

  • 开放活跃染色质可能促进t(11;14)(q13;32)易位,该易位主要在前体B细胞中由重组激活基因介导获得,8%病例在成熟B细胞中由活化诱导胞苷脱氨酶介导。
  • 鉴定出新的复发性MCL驱动基因,包括CDKN1B、SAMHD1、BCOR、SYNE1、HNRNPH1、SMARCB1和DAZAP1。
  • 复杂结构改变是MCL相关早期致癌机制,靶向关键驱动基因;断裂-融合-桥循环和易位激活癌基因BMI1、MIR17HG、TERT、MYC和MYCN,产生基因扩增和重塑调控区域。
  • cMCL的结构变异、拷贝数改变和驱动改变数量显著高于nnMCL,ATM改变为cMCL独有,TP53和TERT改变在nnMCL中略微富集。
  • 多个驱动基因有预后影响,但仅TP53和MYC异常独立于基因组复杂性提供预后价值;基因组复杂性增加、断裂-融合-桥循环和高DNA甲基化改变定义不同临床演变患者。

关键数值与推荐

  • cMCL的结构变异、拷贝数改变和驱动改变数量显著高于nnMCL,ATM改变为cMCL独有,TP53和TERT改变在nnMCL中略微富集。
  • 仅TP53和MYC异常独立于基因组复杂性提供预后价值。
  • 8%病例的t(11;14)(q13;32)易位在成熟B细胞中由活化诱导胞苷脱氨酶介导。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mantle cell lymphoma (MCL) is a mature B-cell neoplasm initially driven by CCND1 rearrangement with 2 molecular subtypes, conventional MCL (cMCL) and leukemic non-nodal MCL (nnMCL), that differ in their clinicobiological behavior. To identify the genetic and epigenetic alterations determining this diversity, we used whole-genome (n = 61) and exome (n = 21) sequencing (74% cMCL, 26% nnMCL) combined with transcriptome and DNA methylation profiles in the context of 5 MCL reference epigenomes. We identified that open and active chromatin at the major translocation cluster locus might facilitate the t(11;14)(q13;32), which modifies the 3-dimensional structure of the involved regions. This translocation is mainly acquired in precursor B cells mediated by recombination-activating genes in both MCL subtypes, whereas in 8% of cases the translocation occurs in mature B cells mediated by activation-induced cytidine deaminase. We identified novel recurrent MCL drivers, including CDKN1B, SAMHD1, BCOR, SYNE1, HNRNPH1, SMARCB1, and DAZAP1. Complex structural alterations emerge as a relevant early oncogenic mechanism in MCL, targeting key driver genes. Breakage-fusion-bridge cycles and translocations activated oncogenes (BMI1, MIR17HG, TERT, MYC, and MYCN), generating gene amplifications and remodeling regulatory regions. cMCL carried significant higher numbers of structural variants, copy number alterations, and driver changes than nnMCL, with exclusive alterations of ATM in cMCL, whereas TP53 and TERT alterations were slightly enriched in nnMCL. Several drivers had prognostic impact, but only TP53 and MYC aberrations added value independently of genomic complexity. An increasing genomic complexity, together with the presence of breakage-fusion-bridge cycles and high DNA methylation changes related to the proliferative cell history, defines patients with different clinical evolution.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Nadeu F, Martin-Garcia D, Clot G, et al. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood. 2020. PMID: 32584970. doi:10.1182/blood.2020005289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。